Lighthouse Financial LLC Buys New Stake in Natera, Inc. $NTRA

Lighthouse Financial LLC purchased a new stake in Natera, Inc. (NASDAQ:NTRA) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 2,012 shares of the medical research company’s stock, valued at approximately $832,000.

A number of other large investors have also recently bought and sold shares of the stock. Yousif Capital Management LLC raised its stake in Natera by 4.8% during the third quarter. Yousif Capital Management LLC now owns 1,905 shares of the medical research company’s stock worth $787,000 after acquiring an additional 87 shares in the last quarter. Private Wealth Partners LLC acquired a new stake in shares of Natera in the 3rd quarter valued at $310,000. MBL Wealth LLC acquired a new stake in shares of Natera in the 3rd quarter valued at $487,000. Compass Wealth Management LLC bought a new stake in shares of Natera in the 3rd quarter worth about $99,000. Finally, Root Financial Partners LLC bought a new stake in shares of Natera in the 3rd quarter worth about $157,000. 99.90% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Natera

In other news, insider Solomon Moshkevich sold 15,160 shares of Natera stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $326.89, for a total transaction of $4,955,652.40. Following the completion of the sale, the insider owned 110,859 shares in the company, valued at $36,238,698.51. The trade was a 12.03% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider John Fesko sold 6,517 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $321.53, for a total transaction of $2,095,411.01. Following the sale, the insider directly owned 197,257 shares of the company’s stock, valued at approximately $63,424,043.21. This trade represents a 3.20% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders have sold 52,985 shares of company stock valued at $16,119,137. 5.05% of the stock is currently owned by company insiders.

Natera Stock Up 0.6%

NTRA stock opened at $403.95 on Friday. Natera, Inc. has a twelve month low of $181.00 and a twelve month high of $437.41. The company has a market cap of $58.23 billion, a P/E ratio of -297.02 and a beta of 1.50. The business has a fifty day moving average of $367.33 and a 200-day moving average of $282.37.

Natera (NASDAQ:NTRA) last posted its quarterly earnings results on Thursday, August 6th. The medical research company reported ($0.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.49) by $0.02. The business had revenue of $752.75 million for the quarter, compared to analysts’ expectations of $661.24 million. Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%. The firm’s quarterly revenue was up 37.7% compared to the same quarter last year. During the same quarter last year, the business earned ($0.74) earnings per share. As a group, equities research analysts anticipate that Natera, Inc. will post -1.02 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the stock. Rothschild & Co Redburn assumed coverage on shares of Natera in a research report on Tuesday, September 8th. They set a “buy” rating and a $385.00 target price for the company. Citigroup boosted their price target on shares of Natera from $365.00 to $480.00 and gave the company a “buy” rating in a research report on Tuesday, October 6th. Morgan Stanley upped their price objective on shares of Natera from $355.00 to $435.00 and gave the stock an “overweight” rating in a research note on Monday, October 12th. Piper Sandler raised their price objective on shares of Natera from $249.00 to $363.50 and gave the stock an “overweight” rating in a report on Wednesday, August 12th. Finally, BTIG Research lifted their target price on shares of Natera from $290.00 to $320.00 and gave the company a “buy” rating in a research note on Friday, August 7th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating, three have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $379.20.

About Natera

Natera, Inc is a diagnostics company that develops and commercializes molecular testing services designed to provide personalized genetic and genomic information. Its tests are used across reproductive health, oncology and organ transplantation, with the company combining next-generation sequencing and bioinformatics to analyze DNA and monitor disease-related signals.

In reproductive health, Natera offers Panorama noninvasive prenatal screening, Horizon carrier screening and Vistara single-gene disorder screening.